However, Combining EC-FAK inhibition with other tumor therapies, such as Doxorubicin for melanoma (Tavora et al., 2014), demonstrated potential effectiveness in suppressing tumor angiogenesis, suggesting distinct effects of FAK inhibition when combined with different cancer types. This evidence concerns the gene PTK2 and cancer.